A
104.08
1.09 (1.06%)
| Previous Close | 102.99 |
| Open | 103.00 |
| Volume | 211,318 |
| Avg. Volume (3M) | 702,775 |
| Market Cap | 5,124,524,544 |
| Price / Earnings (Forward) | 357.14 |
| Price / Sales | 11.50 |
| Price / Book | 79.73 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | -64.39% |
| Operating Margin (TTM) | -45.67% |
| Diluted EPS (TTM) | -5.76 |
| Quarterly Revenue Growth (YOY) | 62.00% |
| Total Debt/Equity (MRQ) | 397.02% |
| Current Ratio (MRQ) | 2.03 |
| Operating Cash Flow (TTM) | -118.32 M |
| Levered Free Cash Flow (TTM) | -20.98 M |
| Return on Assets (TTM) | -26.17% |
| Return on Equity (TTM) | -282.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Axsome Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 5.0 |
| Insider Activity | -2.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.80 |
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 16.31% |
| % Held by Institutions | 76.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alethea Capital Management, Llc | 30 Sep 2024 | 738,503 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 190.00 (Morgan Stanley, 82.55%) | Buy |
| Median | 177.50 (70.54%) | |
| Low | 150.00 (Needham, 44.12%) | Buy |
| Average | 174.50 (67.66%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 109.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 01 Oct 2025 | 179.00 (71.98%) | Buy | 118.46 |
| Wells Fargo | 03 Sep 2025 | 163.00 (56.61%) | Buy | 122.00 |
| B of A Securities | 05 Aug 2025 | 176.00 (69.10%) | Buy | 103.59 |
| RBC Capital | 05 Aug 2025 | 189.00 (81.59%) | Buy | 103.59 |
| Needham | 04 Aug 2025 | 150.00 (44.12%) | Buy | 106.54 |
| Morgan Stanley | 03 Jul 2025 | 190.00 (82.55%) | Buy | 105.44 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| JACOBSON MARK L. | - | 117.49 | -10,000 | -1,174,900 |
| Aggregate Net Quantity | -10,000 | |||
| Aggregate Net Value ($) | -1,174,900 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 117.49 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| JACOBSON MARK L. | Officer | 22 Sep 2025 | Automatic sell (-) | 10,000 | 117.49 | 1,174,900 |
| JACOBSON MARK L. | Officer | 22 Sep 2025 | Option execute | 10,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 17 Sep 2025 | Announcement | Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025 |
| 27 Aug 2025 | Announcement | Axsome Therapeutics to Participate in Upcoming Investor Conferences |
| 04 Aug 2025 | Announcement | Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update |
| 21 Jul 2025 | Announcement | Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline |
| 09 Jul 2025 | Announcement | Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 |
| 07 Jul 2025 | Announcement | Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |